Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Sacituzumab govitecan in metastatic breast cancer: a systematic review and meta-analysis of its clinical benefit and safety. | Front Med (Lausanne) | 2026 | 42827466 | PubTator, text mining | PubMed |
| Biomarker-Driven Treatments for Ovarian Cancer: Moving Beyond HRD? | Int J Womens Health | 2026 | 42824309 | PubTator, text mining | PubMed |
| Antibody-drug conjugates in breast cancer: redefining targeted therapy. | J Clin Invest | 2026 | 42820303 | PubTator, text mining | PubMed |
| Quantitative Systems Pharmacology Model for TROP-2 Targeted Antibody-Drug Conjugate in Triple-Negative Breast Cancer. | bioRxiv | 2026 | 42818000 | PubTator, text mining | PubMed |
| Systemic and intracranial activity of antibody-drug conjugates in patients with non-small cell lung cancer and brain metastases: A systematic review and meta-analysis. | Lung Cancer | 2026 | 42815252 | PubTator, text mining | PubMed |
| Time to Rethink Pathology Reporting in Adenoid Cystic Carcinoma. | Head Neck | 2026 | 42811719 | PubTator, text mining | PubMed |
| A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018). | Eur J Cancer | 2026 | 42810148 | PubTator, text mining | PubMed |
| Dermatologic adverse events associated with Sacituzumab Govitecan: an international retrospective study from the EADV Task Force "Dermatology for Cancer Patients" and pharmacovigilance analysis. | Breast Cancer Res Treat | 2026 | 42804021 | PubTator, text mining | PubMed |
| TROP2-Targeting Chimeras (TRTACs) for Tumor Cell-Selective Membrane Protein Degradation and Enhanced Drug Delivery. | Adv Sci (Weinh) | 2026 | 42801692 | PubTator, text mining | PubMed |
| Antibody-Drug Conjugates in Lung Cancer: Promise, Progress, and Persistent Challenges. | Curr Issues Mol Biol | 2026 | 42793224 | PubTator, text mining | PubMed |
| TROP2 expression in gastric and GEJ adenocarcinomas: associations with clinicopathological features, biomarkers, and treatment outcomes. | ESMO Gastrointest Oncol | 2026 | 42787785 | PubTator, text mining | PubMed |
| Serum human trophoblast cell surface antigen and T-box protein 5 levels play a role in predicting adverse pregnancy outcomes in eclampsia. | J Med Biochem | 2026 | 42780781 | PubTator, text mining | PubMed |
| Neoadjuvant antibody-drug conjugates for early-stage breast cancer: A systematic review and meta-analysis. | Crit Rev Oncol Hematol | 2026 | 42772656 | PubTator, text mining | PubMed |
| NECTIN4, TROP2 and PDL1 in Breast Cancer: Immunohistochemical Profiling and Clinical Associations. | Int J Surg Pathol | 2026 | 42770457 | PubTator, text mining | PubMed |
| Oral toxicities secondary to TROP2 and HER2-directed antibody drug conjugates: a multicenter retrospective cohort study. | Oncologist | 2026 | 42768463 | PubTator, text mining | PubMed |
| Durable Intracranial Response to Sacituzumab Tirumotecan in HER2-Negative Salivary Duct Carcinoma With High TROP2 Expression: A Case Report. | Cancer Rep (Hoboken) | 2026 | 42768404 | PubTator, text mining | PubMed |
| Tumor-associated calcium signal transducer 2 expression as a promising therapeutic target in esophageal squamous cell carcinoma: a combined the Cancer Genome Atlas and an institutional cohort. | Esophagus | 2026 | 42763384 | PubTator, text mining | PubMed |
| Clinical Outcomes of Sacituzumab Govitecan in Breast Cancer: A Systematic Review, Meta-Analysis, and GRADE Assessment of Randomized Evidence. | Am J Clin Oncol | 2026 | 42758906 | PubTator, text mining | PubMed |
| Safety management of anti TROP2 ADCs in patients with breast cancer. | Curr Opin Oncol | 2026 | 42757501 | PubTator, text mining | PubMed |
| Case Report: Radical nephroureterectomy after toripalimab plus disitamab vedotin in biomarker-non-enriched upper tract urothelial carcinoma. | Front Oncol | 2026 | 42755500 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers